The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

GlaxoSmithKline PLC

NYSE: GSK
Last

(U.S.) $46.45

Today's change-0.07 -0.15%
Updated November 28 1:02 PM EST. Delayed by at least 15 minutes.
 

GlaxoSmithKline PLC

NYSE: GSK
Last

(U.S.) $46.45

Today's change-0.07 -0.15%
Updated November 28 1:02 PM EST. Delayed by at least 15 minutes.

Reversal following new 20-day high

GlaxoSmithKline PLC closed lower Friday, dropping (U.S.)$0.07 or 0.15% to (U.S.)$46.45 after setting a new 20-day high. Although unchanged over the last five days, shares are down 13.00% for the last year to date. This security has underperformed the S&P 500 by 25.83% during the last year.

Key company metrics

  • Open(U.S.) $46.53
  • Previous close(U.S.) $46.52
  • High(U.S.) $46.73
  • Low(U.S.) $46.42
  • Bid / Ask(U.S.) $46.46 / (U.S.) $46.88
  • YTD % change-13.00%
  • Volume1,409,717
  • Average volume (10-day)2,896,710
  • Average volume (1-month)3,108,262
  • Average volume (3-month)4,969,582
  • 52-week range(U.S.) $41.91 to (U.S.) $56.73
  • Beta0.65
  • Trailing P/E17.20×
  • P/E 1 year forward15.39×
  • Forward PEG5.13×
  • Indicated annual dividend(U.S.) $2.65
  • Dividend yield5.71%
  • Trailing EPS(U.S.) $2.70
Updated November 28 1:02 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+18.17%

Based on its net profit margin of 18.17%, GlaxoSmithKline PLC is less effective than other companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.87%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue5,6465,5615,6136,906
Total other revenue--------
Total revenue5,6465,5615,6136,906
Gross profit3,8943,8883,9084,773
Total cost of revenue1,7521,6731,7052,133
Total operating expense4,9434,4244,5474,212
Selling / general / administrative1,7951,9691,9192,094
Research & development742766784905
Depreciation / amortization17172323
Interest expense (income), net operating--------
Unusual expense (income)73871186-845
Other operating expenses, total-101-72-70-98
Operating income7031,1371,0662,694
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax5489869032,546
Income after tax3857027192,505
Income tax, total16328418441
Net income4016546682,461
Total adjustments to net income--------
Net income before extra. items4016546682,461
Minority interest16-48-51-44
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items4016546682,461
Inc. avail. to common incl. extra. items4016546682,461
Diluted net income4016546682,461
Dilution adjustment------0
Diluted weighted average shares4,8654,8744,8664,881
Diluted EPS excluding extraordinary itemsvalue per share0.080.130.140.50
Dividends per sharevalue per share0.190.190.190.23
Diluted normalized EPSvalue per share0.210.160.170.25